KRAS and familial pancreatic carcinoma: Nuclear factor erythroid 2(NRF2) can activate metabolic reconnection and increase the pathway involved in glutamine metabolism, which inhibits the chemotherapy resistance of KRAS mutant pancreatic cancer (112).